igeahub.com
Study Results Shows Significantly Higher Response Rates for Taltz (ixekizumab) of Lilly Compared to Stelara (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis - IgeaHub
March 4, 2017 Eli Lilly and Company has announced that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated